SITKA BIOPHARMA

Sitka Biopharma is a preclinical biotechnology company focused on developing its breakthrough nanoparticle platform technology to increase absorption of drugs in difficult-to-penetrate tissues. Initially targeting oncology indications, we are developing our lead candidate (STK-01) to address the absorption challenge of intravesical chemotherapy for bladder cancer, and later intraperitoneal delivery for ovarian cancer. Their nanoparticle platform technology is highly versatile, offers unique b... enefits over other nano-delivery systems, and is particularly well-suited for treating relatively localized diseases where local administration of the therapeutic is possible but is currently ineffective or unsafe. Bladder cancer was chosen for their lead program because it is characterized by therapies that exhibit limited uptake and efficacy, or are associated with significant tolerability issues and side effects. Sitka’s novel product (STK-01) is designed to overcome these issues and improve treatment outcomes by delivering a much higher concentration of the chemotherapeutic docetaxel into the bladder wall.More